Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,578.30 INR | +1.35% |
|
+5.69% | -10.49% |
11/07 | Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR2,870, Keeps at Buy | MT |
30/06 | India's Torrent Pharma to acquire controlling stake in JB Chem and Pharma | RE |
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | 20.01 | 17.37 | 15.12 | 10.52 | 12.41 | |
Return on Total Capital | 26.05 | 22.22 | 19.01 | 13.24 | 15.3 | |
Return On Equity % | 31.75 | 30.3 | 25.99 | 18.79 | 22.58 | |
Return on Common Equity | 32.67 | 30.84 | 26.36 | 18.86 | 22.77 | |
Margin Analysis | ||||||
Gross Profit Margin % | 67.27 | 70.32 | 68.03 | 65.68 | 67.87 | |
SG&A Margin | 27.39 | 29.03 | 26.9 | 26.43 | 28.08 | |
EBITDA Margin % | 26.66 | 27.38 | 26.17 | 21.77 | 24.54 | |
EBITA Margin % | 25.14 | 25.72 | 24.39 | 19.91 | 22.31 | |
EBIT Margin % | 25.04 | 25.55 | 24.13 | 18.15 | 20.82 | |
Income From Continuing Operations Margin % | 17.99 | 20.78 | 18.67 | 14.97 | 18.79 | |
Net Income Margin % | 17.55 | 20.33 | 18.42 | 14.65 | 18.51 | |
Net Avail. For Common Margin % | 17.55 | 20.33 | 18.42 | 14.65 | 18.51 | |
Normalized Net Income Margin | 15.33 | 15.89 | 14.7 | 11.38 | 13.48 | |
Levered Free Cash Flow Margin | 12.82 | 9.44 | -20.85 | 8.13 | 11.75 | |
Unlevered Free Cash Flow Margin | 13.05 | 9.64 | -20.4 | 8.42 | 11.93 | |
Asset Turnover | ||||||
Asset Turnover | 1.28 | 1.09 | 1 | 0.93 | 0.95 | |
Fixed Assets Turnover | 3.31 | 3.23 | 3.55 | 3.24 | 3.36 | |
Receivables Turnover (Average Receivables) | 15.63 | 14.45 | 21.65 | 18.14 | 14.51 | |
Inventory Turnover (Average Inventory) | 2.23 | 1.77 | 1.69 | 1.84 | 2.18 | |
Short Term Liquidity | ||||||
Current Ratio | 2.26 | 2.89 | 1.68 | 2.32 | 3.1 | |
Quick Ratio | 1.29 | 1.78 | 0.64 | 1.14 | 2.02 | |
Operating Cash Flow to Current Liabilities | 0.88 | 0.86 | 0.35 | 0.97 | 1.02 | |
Days Sales Outstanding (Average Receivables) | 23.41 | 25.27 | 16.86 | 20.12 | 25.23 | |
Days Outstanding Inventory (Average Inventory) | 163.79 | 205.77 | 215.94 | 198.03 | 168.19 | |
Average Days Payable Outstanding | 119.6 | 120.9 | 103.82 | 138.78 | 114.45 | |
Cash Conversion Cycle (Average Days) | 67.61 | 110.14 | 128.98 | 79.37 | 78.97 | |
Long Term Solvency | ||||||
Total Debt/Equity | 3.63 | 5.75 | 13.99 | 2.23 | 2.16 | |
Total Debt / Total Capital | 3.51 | 5.44 | 12.27 | 2.19 | 2.12 | |
LT Debt/Equity | 1.66 | 1.27 | 0.83 | 0.37 | 0.34 | |
Long-Term Debt / Total Capital | 1.6 | 1.2 | 0.72 | 0.36 | 0.33 | |
Total Liabilities / Total Assets | 27.63 | 23.69 | 30.95 | 21.53 | 19.96 | |
EBIT / Interest Expense | 68.24 | 82.67 | 33.66 | 39.44 | 75.24 | |
EBITDA / Interest Expense | 72.7 | 88.67 | 36.56 | 47.4 | 88.86 | |
(EBITDA - Capex) / Interest Expense | 62.13 | 72.64 | 28.22 | 27.81 | 77.83 | |
Total Debt / EBITDA | 0.09 | 0.16 | 0.43 | 0.09 | 0.08 | |
Net Debt / EBITDA | -0.61 | -1.01 | -0.19 | -0.71 | -1.25 | |
Total Debt / (EBITDA - Capex) | 0.1 | 0.2 | 0.56 | 0.15 | 0.09 | |
Net Debt / (EBITDA - Capex) | -0.71 | -1.24 | -0.24 | -1.21 | -1.43 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | 17.91 | 6 | 25.22 | 12.44 | 18.12 | |
Gross Profit, 1 Yr. Growth % | 22.35 | 10.8 | 21.21 | 8.55 | 22.06 | |
EBITDA, 1 Yr. Growth % | 67.31 | 8.84 | 19.51 | -4.31 | 33.15 | |
EBITA, 1 Yr. Growth % | 69.66 | 8.45 | 18.55 | -5.96 | 32.34 | |
EBIT, 1 Yr. Growth % | 69.14 | 8.14 | 18.06 | -13.32 | 35.48 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 73 | 22.43 | 12.37 | -9.86 | 48.26 | |
Net Income, 1 Yr. Growth % | 78.11 | 22.81 | 13.28 | -10.58 | 49.23 | |
Normalized Net Income, 1 Yr. Growth % | 81.3 | 9.88 | 15.62 | -12.97 | 39.93 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 78.12 | 22.82 | 13.27 | -10.57 | 49 | |
Accounts Receivable, 1 Yr. Growth % | 141.17 | -37.75 | 17.41 | 48.5 | 47.16 | |
Inventory, 1 Yr. Growth % | 9.52 | 31.63 | 48.73 | -14.87 | 3.67 | |
Net Property, Plant and Equip., 1 Yr. Growth % | 11.06 | 6.82 | 19.98 | 26.26 | 4.03 | |
Total Assets, 1 Yr. Growth % | 23.36 | 25.61 | 43.55 | 6.21 | 23.14 | |
Tangible Book Value, 1 Yr. Growth % | 23.94 | 36.17 | -9.02 | 32.77 | 35.77 | |
Common Equity, 1 Yr. Growth % | 23.46 | 35.48 | 30.35 | 20.8 | 25.93 | |
Cash From Operations, 1 Yr. Growth % | 82.66 | 9.1 | -19.12 | 97.15 | 18.7 | |
Capital Expenditures, 1 Yr. Growth % | -23.42 | 35.29 | 52.21 | 69.73 | -60.03 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -21.91 | -379.11 | -143.45 | 70.67 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -21.71 | -367.56 | -145.97 | 67.26 | |
Dividend Per Share, 1 Yr. Growth % | -30.34 | - | - | - | - | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | 11.79 | 15.12 | 18.66 | 15.24 | |
Gross Profit, 2 Yr. CAGR % | - | 16.44 | 15.77 | 14.71 | 15.11 | |
EBITDA, 2 Yr. CAGR % | - | 34.95 | 14.05 | 5.74 | 12.87 | |
EBITA, 2 Yr. CAGR % | - | 35.65 | 13.39 | 4.32 | 11.56 | |
EBIT, 2 Yr. CAGR % | - | 35.24 | 12.99 | -0.06 | 8.37 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 45.54 | 17.29 | 0.64 | 15.6 | |
Net Income, 2 Yr. CAGR % | - | 47.9 | 17.95 | 0.65 | 15.52 | |
Normalized Net Income, 2 Yr. CAGR % | - | 41.15 | 12.72 | 0.31 | 10.36 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 47.91 | 17.95 | 0.65 | 15.44 | |
Accounts Receivable, 2 Yr. CAGR % | - | 22.53 | -14.51 | 32.04 | 47.83 | |
Inventory, 2 Yr. CAGR % | - | 20.07 | 39.92 | 12.52 | -6.06 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 8.92 | 13.21 | 23.08 | 14.61 | |
Total Assets, 2 Yr. CAGR % | - | 24.48 | 34.28 | 23.47 | 14.36 | |
Tangible Book Value, 2 Yr. CAGR % | - | 29.91 | 11.31 | 9.91 | 34.26 | |
Common Equity, 2 Yr. CAGR % | - | 29.33 | 32.89 | 25.48 | 23.34 | |
Cash From Operations, 2 Yr. CAGR % | - | 39.58 | -7.38 | 26.27 | 52.98 | |
Capital Expenditures, 2 Yr. CAGR % | - | 1.79 | 42.8 | 60.73 | -17.64 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 46.83 | 10.65 | -13.88 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 43.96 | 11.44 | -12.31 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | 16.04 | 14.22 | 18.48 | |
Gross Profit, 3 Yr. CAGR % | - | - | 17.92 | 13.31 | 17.11 | |
EBITDA, 3 Yr. CAGR % | - | - | 29.59 | 6.77 | 14.19 | |
EBITA, 3 Yr. CAGR % | - | - | 29.69 | 5.68 | 12.93 | |
EBIT, 3 Yr. CAGR % | - | - | 29.26 | 2.6 | 10.6 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 33.51 | 7.44 | 14.52 | |
Net Income, 3 Yr. CAGR % | - | - | 35.32 | 7.55 | 14.77 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 32.07 | 3.41 | 12.08 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 35.32 | 7.55 | 14.71 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | 20.8 | 2.77 | 36.9 | |
Inventory, 3 Yr. CAGR % | - | - | 28.95 | 18.56 | 9.49 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 12.49 | 17.4 | 16.37 | |
Total Assets, 3 Yr. CAGR % | - | - | 30.54 | 24.18 | 23.36 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 15.37 | 18.05 | 17.93 | |
Common Equity, 3 Yr. CAGR % | - | - | 29.67 | 28.73 | 25.63 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 15.28 | 19.14 | 23.7 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | 16.02 | 51.26 | 1.07 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | -1.84 | 27.84 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | -1.29 | 27.59 | |
Compound Annual Growth Rate Over Five Years | ||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 15.72 | |
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 16.79 | |
EBITDA, 5 Yr. CAGR % | - | - | - | - | 22.08 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | 21.52 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 19.87 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 26.04 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 27.02 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 22.91 | |
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | 26.99 | |
Accounts Receivable, 5 Yr. CAGR % | - | - | - | - | 30.96 | |
Inventory, 5 Yr. CAGR % | - | - | - | - | 13.6 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 13.33 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 23.81 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 22.58 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 27.1 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 29.09 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 1.16 |
- Stock Market
- Equities
- MANKIND Stock
- Financials Mankind Pharma Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition